Table 2.
Comparison between patients with and without AFP response
| Variables | Patients with AFP response (n=43; 34.1%) | Patients without AFP response (n=83; 65.9%) | P-value |
|---|---|---|---|
| Demographic variables | |||
| Age, years | 56 (39–78) | 59 (34–85) | NS |
| Male sex | 38 (88.4) | 68 (76.4) | NS |
| Viral etiology | 34 (89.5) | 61 (83.6) | NS |
| ECOG, 0–1 | 42 (97.7) | 84 (94.4) | NS |
| Child-Pugh class A | 33 (76.7) | 67 (75.3) | NS |
| Previous treatment history | 30 (69.8) | 64 (71.9) | NS |
| Tumor variables | |||
| Tumor size, cm | 4.0 (2.0–13.0) | 3.2 (2.0–18.0) | NS |
| Multiple tumors, ≥4 | 27 (62.8) | 47 (52.8) | NS |
| Infiltrative type | 20 (46.5) | 34 (38.2) | NS |
| Portal vein invasion | 14 (32.6) | 37 (41.6) | NS |
| Presence of EHS and/or RNI | 30 (69.8) | 62 (69.7) | NS |
| Laboratory variables | |||
| Alanine aminotransferase, IU/dL | 25 (3.0–315.0) | 30.0 (9.0–433.0) | NS |
| Prothrombin time, INR | 1.1 (0.9–2.2) | 1.1 (0.9–1.7) | NS |
| Total bilirubin, mg/dL | 0.7 (0.3–2.1) | 0.8 (0.3–3.6) | NS |
| Serum albumin, mg/dL | 3.8 (2.6–4.6) | 3.9 (2.6–5.0) | NS |
| Tumor markers | |||
| AFP, mg/dL | 450.9 (22–120,000) | 343.2 (22.5–120,000) | NS |
| PIVKA-II, mAU/mL | 365.0 (9.0–20,000) | 529.0 (9.0–75,000) | NS |
| Disease control rate | 31 (72.1) | 39 (47.0) | 0.007 |
Note: Values are expressed as median (range) or number (%).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EHS, extrahepatic spread; RNI, regional nodal involvement; INR, international normalized ratio; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; NS, not significant.